Feb 13, 2020
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
Feb 03, 2020
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
Jan 31, 2020
Lilly's REYVOW(TM) (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription
Jan 24, 2020
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
Jan 23, 2020
Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)
Jan 10, 2020
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
Nov 15, 2019
Claim compensation in the Avandia drug Canada-wide settlement
Nov 07, 2019
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
Oct 28, 2019
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Oct 28, 2019
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Sep 29, 2019
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Sep 27, 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Sep 20, 2019
Bayer data at ESMO 2019 highlights innovation in cancer research
Sep 20, 2019
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Sep 19, 2019
Addition of KISQALI® to drug plan in Quebec expands access to treatment for metastatic breast cancer
Sep 17, 2019
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Aug 07, 2019
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Jul 30, 2019
Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Jul 21, 2019
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
Jul 09, 2019
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST